• 1. Characterization of the laccase-mediated oligomerization of 4-hydroxybenzoic acid
  Sjoerd Slagman,Jorge Escorihuela,Han Zuilhof,Maurice C. R. Franssen RSC Adv. 2016 6 99367
• 2. 198. 1-Phenylnaphthalenes. Part IV. The cyclisation of methyl hydrogen cis- and trans-γ-o-methoxyphenyl- and ethyl hydrogen cis- and trans-γ-p-methoxyphenyl-γ-phenylitaconate to the corresponding 1-phenylnaphthalenes
  F. G. Baddar,Lanson S. El-Assal,Victorine B. Baghos J. Chem. Soc. 1958 986
• 3. β-Aroylpropionic acids. Part V. The synthesis of β-aroyl-α-methylpropionic acids, and their conversion into polynuclear compounds
  F. G. Baddar,Hussein A. Fahim,Abdallah M. Fleifel J. Chem. Soc. 1955 2199
• 4. Notes
  J. Quarterman,T. S. Stevens,G. D. Parkes,K. J. Clark,R. L. Huang,M. Balasubramanian,V. Baliah,T. Rangarajan,Lindsay H. Briggs,A. R. Taylor,M. Z. Barakat,S. K. Shehab,M. M. El-Sadr,G. Hetherington,D. R. Hub,M. J. Nichols,P. L. Robinson,F. G. Baddar,H. A. Fahim,A. M. Fleifel,V. Gold,J. Hilton,E. N. Morgan,E. M. Tanner,C. Eaborn,R. A. Shaw,G. W. H. Cheeseman J. Chem. Soc. 1955 3292

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Methoxybenzoic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Methyl 3-iodo-4-methoxybenzoate (CAS No. 35387-93-0): A Key Intermediate in Modern Pharmaceutical Synthesis

Methyl 3-iodo-4-methoxybenzoate, identified by its Chemical Abstracts Service (CAS) number 35387-93-0, is a significant compound in the realm of pharmaceutical chemistry. This organometallic derivative serves as a crucial intermediate in the synthesis of various bioactive molecules, particularly in the development of novel therapeutic agents. Its unique structural features, combining an iodo substituent with a methoxy group on a benzoate backbone, make it a versatile building block for medicinal chemists.

The compound's molecular structure, characterized by a benzene ring substituted with an iodine atom at the 3-position and a methoxy group at the 4-position, imparts distinct reactivity that is highly valuable in synthetic chemistry. The presence of the iodo group enhances its utility as a coupling partner in cross-coupling reactions, such as Suzuki-Miyaura and Stille couplings, which are fundamental in constructing complex organic molecules. These reactions are pivotal in drug discovery, enabling the rapid assembly of intricate structures that mimic natural products or target specific biological pathways.

In recent years, the pharmaceutical industry has witnessed a surge in the use of heterocyclic compounds due to their diverse biological activities. Methyl 3-iodo-4-methoxybenzoate has emerged as a preferred precursor in the synthesis of various heterocycles, including flavonoids and benzodiazepines. Its ability to undergo facile functionalization makes it an indispensable tool for medicinal chemists seeking to optimize drug candidates. For instance, recent studies have demonstrated its role in generating novel analogs with enhanced pharmacological properties, such as improved solubility and reduced toxicity.

The compound's significance extends beyond its role as a synthetic intermediate. It has been explored in the development of targeted therapies for neurological disorders, where precise molecular modifications are essential for efficacy and safety. Researchers have leveraged its structural framework to design molecules that interact selectively with specific receptors or enzymes implicated in conditions like Alzheimer's disease and Parkinson's disease. The methoxy group, in particular, has been shown to modulate electronic properties and binding affinity, making it a critical parameter in structure-activity relationship studies.

The iodo substituent on Methyl 3-iodo-4-methoxybenzoate also facilitates its use in radiolabeling applications, where radioisotopes are incorporated into drug candidates for diagnostic imaging or therapeutic purposes. This has opened new avenues in nuclear medicine, allowing for more accurate disease detection and treatment monitoring. The compound's stability under various reaction conditions further enhances its appeal as a radiolabeling precursor, ensuring consistent results across different experimental protocols.

The synthesis of Methyl 3-iodo-4-methoxybenzoate typically involves multi-step processes that require careful optimization to achieve high yields and purity. Advanced synthetic methodologies, such as palladium-catalyzed cross-coupling reactions and metal-halogen exchange protocols, have been employed to streamline its production. These techniques not only improve efficiency but also minimize unwanted byproducts, ensuring that the final product meets stringent pharmaceutical standards.

The compound's role in drug development is further underscored by its incorporation into several clinical trials investigating novel therapeutic approaches. By serving as a scaffold for generating lead compounds, Methyl 3-iodo-4-methoxybenzoate has contributed to advancements across multiple therapeutic areas. Its versatility allows researchers to explore diverse chemical space rapidly, accelerating the discovery of next-generation drugs that address unmet medical needs.

In conclusion, Methyl 3-iodo-4-methoxybenzoate (CAS No. 35387-93-0) is a cornerstone in modern pharmaceutical synthesis. Its unique structural attributes and reactivity make it an indispensable tool for medicinal chemists engaged in drug discovery and development. As research continues to uncover new applications for this compound, its importance is set to grow even further, driving innovation in pharmaceutical chemistry and contributing to the creation of safer and more effective treatments for patients worldwide.

• 15126-06-4(Methyl 4-hydroxy-3-iodobenzoate)
• 35387-92-9(Methyl 4-iodo-3-methoxybenzoate)
• 1131614-42-0(Methyl 4-butoxy-3-iodobenzoate)
• 1131614-40-8(Ethyl 4-acetoxy-3-iodobenzoate)
• 1131588-12-9(3-Iodo-4-propoxybenzoic acid)
• 68507-19-7(3-Iodo-4-methoxybenzoic acid)
• 207115-38-6(Ethyl 3-iodo-4-methoxybenzoate)
• 741699-04-7(Ethyl 3-ethoxy-4-iodobenzoate)
• 82998-76-3(4-Ethoxy-3-iodobenzoic acid)
• 1131614-46-4(Ethyl 3-iodo-4-propoxybenzoate)